Search results
Billionaire Harvard Professor’s Fortune Jumps Nearly $200 Million On News Of Eli Lilly Biotech Deal
Forbes· 18 hours agoNow, he’s set to receive a nine-digit windfall from pharma giant Eli Lilly’s $3.2 billion...
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
Zacks via Yahoo Finance UK· 14 hours agoThe NYSE ARCA Pharmaceutical Index declined 1.67...rose the most (1.0%), while Merck and AbbVie...
Hair Oil Gets a Slick Reboot
New York Times· 14 hours agoHair oiling days for the comedian and actress Lilly Singh were always a family affair. The entire Singh clan — including her cousins, aunties and uncles...
Why the weight-loss drug boom is just the beginning
LoveMONEY via Yahoo Finance UK· 4 days agoFind out how Ozempic, Mounjaro, and other medicines are helping to revolutionise weight loss around the world... and how much people are willing to pay...
Novo, Lilly Fall After Biden Calls for Cheaper Obesity Drugs
Bloomberg via Yahoo Finance UK· 6 days ago(Bloomberg) -- Novo Nordisk A/S and Eli Lilly & Co. shares fell Tuesday after US President Joe Biden...
A New Alzheimer’s Drug May Be the Most Effective One Yet
Time via Yahoo News UK· 5 days agoLilly is collaborating with Roche to make the test more available to doctors who can order it as a...
Approval of Newest Alzheimer’s Drug Will Accelerate New Era of Treatment
The Wall Street Journal· 6 days agoLilly's Kisunla was shown in a study to slow the decline of Alzheimer's patients.
New Drug Approved for Early Alzheimer’s
New York Times· 6 days agoThe drug, by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also...
Bankers Investment Trust: Why TSMC is a safer bet than Nvidia | Trustnet
TrustNet· 4 days agoGlobal stock markets have become obsessed with a narrow group of winners, such as chipmaker Nvidia and obesity drug manufacturers Novo Nordisk and Eli & ...
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
CNN via Yahoo News UK· 6 days agoThe US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
